Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress

Autor: Alfieri, Rr, Bonelli, Ma, Cavazzoni, A, Brigotti, M, Fumarola, C, Sestili, P, Mozzoni, P, DE PALMA, Giuseppe, Mutti, A, Carnicelli, D, Vacondio, F, Silva, C, Borghetti, Af, Wheeler, Kp, Petronini, Pg

Exposure of C2C12 muscle cells to hypertonic stress induced an increase in cell content of creatine transporter mRNA and of creatine transport activity, which peaked after about 24 h incubation at 0.45 osmol (kg H(2)O)(-1). This induction of transpor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6777749bb2218b73575ff998c73a3938
http://hdl.handle.net/11585/34350

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models

Autor: Erika Martinelli, Roberta Alfieri, Vincenza Ciaramella, Silvia La Monica, Teresa Troiani, Carminia Maria Della Corte, Elena Vigliar, Maria Domenica Castellone, Fortunato Ciardiello, Pier Giorgio Petronini, Floriana Morgillo, Giancarlo Troncone, Francesco Pepe, Claudia Cardone, Umberto Malapelle

Publikováno v: Journal of thoracic oncology 13 (2018): 810–820. doi:10.1016/j.jtho.2018.02.025
info:cnr-pdr/source/autori:Della Corte C.M.; Ciaramella V.; Cardone C.; La Monica S.; Alfieri R.; Petronini P.G.; Malapelle U.; Vigliar E.; Pepe F.; Troncone G.; Castellone M.D.; Troiani T.; Martinelli E.; Ciardiello F.; Morgillo F./titolo:Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models/doi:10.1016%2Fj.jtho.2018.02.025/rivista:Journal of thoracic oncology/anno:2018/pagina_da:810/pagina_a:820/intervallo_pagine:810–820/volume:13

Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c2c6139f2410784cecb3ba38fffba0
http://hdl.handle.net/11591/393087

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Autor: Pier Giorgio Petronini, Matteo Goldoni, Sara Tagliaferri, Maricla Galetti, Marzia Capelletti, Andrea Ardizzoni, Marcello Tiseo, Mara Bonelli, Daniele Generali, Silvia La Monica, Roberta Alfieri, Antonio Mutti, Andrea Cavazzoni, Claudia Fumarola

Publikováno v: Biochemical Pharmacology
Biochemical Pharmacology, Elsevier, 2009, 78 (5), pp.460. ⟨10.1016/j.bcp.2009.04.033⟩

The epidermal growth factor receptor(EGFR) is a validated target for therapy in non-small cell lung cancer (NSCLC). Most patients, however, either do not benefit or develop resistance to specific inhibitors of the EGFR tyrosine kinase activity, such

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55171a00b2dee1733d86daefb7ea1294
https://doi.org/10.1016/j.bcp.2009.04.033

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

Autor: Maura Loprevite, Cecilia Bozzetti, Matteo Goldoni, Andrea Ardizzoni, Beatrice Bortesi, Maricla Galetti, Roberta Camisa, Andrea Cavazzoni, Marcello Tiseo, Guido Rindi, Vittorio Franciosi, Giuseppe De Palma, Roberta Alfieri, Paola Mozzoni, Luca Boni, Pier Giorgio Petronini, Marzia Capelletti

Publikováno v: ResearcherID

Introduction: Epidermal growth factor receptor (EGFR) gene intron I contains a polymorphic single sequence dinucleotide repeat (CA), whose length has been found to inversely correlate with transcriptional activity. This study was designed to assess t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9e0bc193a5a611cffa05bd05de0031
http://hdl.handle.net/11379/26479

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Autor: Cavazzoni A; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy., Salamon I; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Fumarola C; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy., Gallerani G; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Laprovitera N; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Gelsomino F; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Riefolo M; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Rihawi K; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Porcellini E; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Rossi T; Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola 47014, Italy., Mazzeschi M; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Naddeo M; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Serravalle S; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Broseghini E; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy., Agostinis F; Department of Biology, University of Padova, 35031 Padua, Italy., Deas O; XenTech, Evry 91100, France., Roncarati R; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy; Istituto di Genetica Molecolare 'Luigi Luca Cavalli-Sforza' (IGM)- Consiglio Nazionale delle Ricerche (CNR), 40136 Bologna, Italy., Durante G; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Pace I; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Lauriola M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Garajova I; Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy., Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Bonafè M; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., D'Errico A; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Petronini PG; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy., Cairo S; XenTech, Evry 91100, France., Ardizzoni A; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy., Sales G; Department of Biology, University of Padova, 35031 Padua, Italy., Ferracin M; IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy. Electronic address: manuela.ferracin@unibo.it.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Oct 02; Vol. 32 (10), pp. 3650-3668. Date of Electronic Publication: 2024 Jul 20.